Do you want to read an article? Please log in or register.
Cystic fibrosis year in review 2025
Pulmonary Fibrosis
RECOMMENDED
Related content
Pulmonary Fibrosis
LONGITUDE: An observational study of the long-term effectiveness of elexacaftor/tezacaftor/ivacaftor in people aged ≥12 years with cystic fibrosis using data from the United Kingdom Cystic Fibrosis Registry - 2-year analysis
J Cyst Fibros
Vega-Hernandez G, MacGregor G, Wilfin A, Adams F, Haugh C, Baxter CA, Wöhling H, Clarke SL, Charman SC, Carr SB
doi: 10.1016/j.jcf.2025.04.012
RECOMMENDED
Pulmonary Fibrosis
BEAT-CF (Bayesian Evidence Adaptive Treatment for people with Cystic Fibrosis): description of a prospective cohort for nested studies in cystic fibrosis
★ 1
Recommended by
Dr Martin Frey, Faculty Member
Respir Med
Fathima P, Pan E, Marsh J, Newall N, Meares T, McLeod C, Shanthikumar S, Jaffe A, Tai A, Ward N, Sivam S, Selvadurai H, Schultz A, Snelling T
doi: 10.1016/j.rmed.2025.108080
Pulmonary Fibrosis
Improvements in health-related quality of life in people with cystic fibrosis ≥6 years of age treated with vanzacaftor/tezacaftor/deutivacaftor
J Cyst Fibros
Wainwright CE, Thorat T, Conner S, Quon BS, Duckers J, Lou Y, Mo C, Xue Y, Zhu L, McGarry L
doi: 10.1016/j.jcf.2025.11.014
RECOMMENDED
Pulmonary Fibrosis
Severe hepatotoxicity is uncommon following the introduction of Elexacaftor/Tezacaftor/Ivacaftor: A real-world two-years follow-up study of the Danish cystic fibrosis cohort
★ 1
Recommended by
Dr Martin Frey, Faculty Member
J Cyst Fibros
Højte C, Olsen MF, Faurholt-Jepsen D, Jørgensen MH, Pressler T, Leo-Hansen C, Bryrup T, Jeppesen M, Olesen HV, Petersen J, Katzenstein TL, Nielsen BU, Skov M, TransformCF Study Group
doi: 10.1016/j.jcf.2025.08.008
RECOMMENDED
Pulmonary FibrosisPneumonia
Diagnostic Accuracy of ancillary tests in Diagnosis of Cystic Fibrosis and development of Cystic Fibrosis Clinical Diagnostic Score: A multicentre prospective cohort study
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Respir Med
Dhochak N, Lodha R, Jat KR, Iqbal J, Kumar P, Goyal JP, Varkki S, Kabra SK, CF study group in alphabetical order with equal contribution
doi: 10.1016/j.rmed.2025.108087
RECOMMENDED
Pulmonary Fibrosis
Exploring the utilisation and effectiveness of implementation science strategies by cystic fibrosis registries for healthcare improvement: a systematic review
★ 1
Recommended by
Dr Martin Frey, Faculty Member
Eur Respir Rev
Stirling RG, Sood B, Stirling MJL, Kotsimbos T, Keating DT, Rang CE, Trauer JM, Young AC, Yu C, Bailey J, Wark P, Melder A, Dawkins P
doi: 10.1183/16000617.0227-2024
RECOMMENDED
Pulmonary FibrosisBronchi
Efficacy of Anti-Inflammatory Therapies for Adults with Non-Cystic Fibrosis Bronchiectasis: A Systematic Review and Network Meta-Analysis
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Chest
Yamamoto S, Niitsu T, Fukushima K, Shiozawa A, Imai R, Hashimoto K, Olivier KN, Aksamit TR, Morimoto K
doi: 10.1016/j.chest.2025.12.035
RECOMMENDED
Pulmonary Fibrosis
The diagnostic challenge of pancreatic cysts in patients with cystic fibrosis: a case series and review of the literature
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
J Cyst Fibros
Fleurent A, Miseur B, Weynand B, Topal H, Dupont L, van Malenstein H
doi: 10.1016/j.jcf.2026.02.007
Further Publications
Sweat chloride and lung function responses to elexacaftor-tezacaftor-ivacaftor in people with cystic fibrosis with two versus one responsive CFTR variants: an analysis of two real-world observational studies
Lancet Respir Med
Burgel PR, Da Silva J, Girodon E, Durieu I, Reynaud-Gaubert M, Murris-Espin M, Chiron R, Grenet D, Ramel S, Mely L, Hamidfar R, Douvry B, Houdouin V, Audousset C, Macey J, Mittaine M, Weiss L, Cosson L, Danner-Boucher I, Reix P, Baravalle M, Burnet E, Sermet-Gaudelus I, Martin C, Paillasseur JL, French Cystic Fibrosis Reference Network study group
doi: 10.1016/S2213-2600(25)00190-0